English

Intellipharmaceutics International Inc.

EDGAR

IPCIF Report (type unavailable) · filed 2024-06-14

319 filing records in this dataset, filed from 2009-10-22 to 2024-06-14. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

480 thousand USD

2023 Q2 · USD

Exact inputs and evidence

Revenue: 480203 USD Source

Operating margin

-6.53%

2023 Q2 · %

Exact inputs and evidence

Operating Income: -31355 USD Source
Revenue: 480203 USD Source

Operating cash flow

89.7 thousand USD

2023 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: 89728 USD Source

Cash and cash equivalents: 69.5 thousand USD 2023-02-28 Source
Exact value

69546 USD
Long-term debt including current maturities: Not available
Shares outstanding: 33.1 million shares 2023-08-31 Source
Exact value

33092665 shares

Reported share-count change

0.00% · 0 shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

33092665 shares · 2022-08-31· Source
33092665 shares · 2023-08-31· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

855 thousand USD

2022-06-01 – 2023-05-31

Exact inputs and evidence

Revenue: 19068 USD · 2022-06-01 – 2022-08-31 Source
Revenue: 65728 USD · 2021-12-01 – 2022-11-30 Source
Revenue: 36046 USD · 2021-12-01 – 2022-08-31 Source
Revenue: 326343 USD · 2022-12-01 – 2023-02-28 Source
Revenue: 480203 USD · 2023-03-01 – 2023-05-31 Source

Net income

-3.18 million USD

2022-09-01 – 2023-08-31

Exact inputs and evidence

Net income: -2892394 USD · 2021-12-01 – 2022-11-30 Source
Net income: -2013191 USD · 2021-12-01 – 2022-08-31 Source
Net income: -355738 USD · 2022-12-01 – 2023-02-28 Source
Net income: -54121 USD · 2023-03-01 – 2023-05-31 Source
Net income: -1889227 USD · 2023-06-01 – 2023-08-31 Source

Operating cash flow

120 thousand USD

2022-09-01 – 2023-08-31

Exact inputs and evidence

Operating cash flow: -1388223 USD · 2021-12-01 – 2022-11-30 Source
Operating cash flow: -1192296 USD · 2021-12-01 – 2022-08-31 Source
Operating cash flow: -14176 USD · 2022-12-01 – 2023-02-28 Source
Operating cash flow: 89728 USD · 2023-03-01 – 2023-05-31 Source
Operating cash flow: 240828 USD · 2023-06-01 – 2023-08-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2024-06-14.

Financial data available through: 2022-11-30.

Financial coverage is incomplete. Newer filings are recorded, but comparable financial figures for those periods are not available here yet.

Coverage by financial measure

Revenue: 10 of 11 periods available· newest 2022-11-30
Operating income: 6 of 11 periods available· newest 2022-11-30
Net income: 10 of 11 periods available· newest 2022-11-30
Operating cash flow: 10 of 11 periods available· newest 2022-11-30
Capital expenditure: 10 of 11 periods available· newest 2022-11-30
Total assets: 10 of 11 periods available· newest 2022-11-30
Total liabilities: 10 of 11 periods available· newest 2022-11-30
Current assets: 10 of 11 periods available· newest 2022-11-30
Current liabilities: 9 of 11 periods available· newest 2022-11-30
Cash and cash equivalents: 11 of 11 periods available· newest 2022-11-30
long term debt: No compatible figures in this window
Shares outstanding: 11 of 11 periods available· newest 2022-11-30

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+USD 65,728

Prior period

USD 0

2020-12-01 – 2021-11-30
Current period

USD 65,728

2021-12-01 – 2022-11-30

Exact inputs and evidence

65728 − 0 = 65728 USD

0 USD · 2020-12-01 – 2021-11-30
Inspect prior input Prior source
65728 USD · 2021-12-01 – 2022-11-30
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Intellipharmaceutics International Inc. · 2022-11-30 Intellipharmaceutics International Inc. (edgar:1474835) Year-over-year change in Revenue: 65728 USD Concept: fundies:Revenue Period: 2021-12-01 to 2022-11-30 Values: Latest reported Published: 2026-11-02T17:49:58Z Snapshot: 905284645addbe579a68ba4ce1d88a662b1b8ecbf27fcec4237c539a4d41962c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1474835?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 65728 USD (2021-12-01 to 2022-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1474835/000165495424001327/ipii_20f.htm#2456185 Filing: 000165495424001327 Input fundies:Revenue: 0 USD (2020-12-01 to 2021-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1474835/000165495424001327/ipii_20f.htm#2456872 Filing: 000165495424001327
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 2.25 million

Prior period

−USD 5.15 million

2020-12-01 – 2021-11-30
Current period

−USD 2.89 million

2021-12-01 – 2022-11-30

Exact inputs and evidence

-2892394 − -5145155 = 2252761 USD

-5145155 USD · 2020-12-01 – 2021-11-30
Inspect prior input Prior source
-2892394 USD · 2021-12-01 – 2022-11-30
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Intellipharmaceutics International Inc. · 2022-11-30 Intellipharmaceutics International Inc. (edgar:1474835) Year-over-year change in Net income: 2252761 USD Concept: fundies:NetIncome Period: 2021-12-01 to 2022-11-30 Values: Latest reported Published: 2026-11-02T17:49:58Z Snapshot: 905284645addbe579a68ba4ce1d88a662b1b8ecbf27fcec4237c539a4d41962c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1474835?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -2892394 USD (2021-12-01 to 2022-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1474835/000165495424001327/ipii_20f.htm#1775241 Filing: 000165495424001327 Input fundies:NetIncome: -5145155 USD (2020-12-01 to 2021-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1474835/000165495424001327/ipii_20f.htm#1775481 Filing: 000165495424001327
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 1.07 million

Prior period

−USD 2.46 million

2020-12-01 – 2021-11-30
Current period

−USD 1.39 million

2021-12-01 – 2022-11-30

Exact inputs and evidence

-1388223 − -2461329 = 1073106 USD

-2461329 USD · 2020-12-01 – 2021-11-30
Inspect prior input Prior source
-1388223 USD · 2021-12-01 – 2022-11-30
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Intellipharmaceutics International Inc. · 2022-11-30 Intellipharmaceutics International Inc. (edgar:1474835) Year-over-year change in Operating cash flow: 1073106 USD Concept: fundies:OperatingCashFlow Period: 2021-12-01 to 2022-11-30 Values: Latest reported Published: 2026-11-02T17:49:58Z Snapshot: 905284645addbe579a68ba4ce1d88a662b1b8ecbf27fcec4237c539a4d41962c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1474835?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -1388223 USD (2021-12-01 to 2022-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1474835/000165495424001327/ipii_20f.htm#1726876 Filing: 000165495424001327 Input fundies:OperatingCashFlow: -2461329 USD (2020-12-01 to 2021-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1474835/000165495424001327/ipii_20f.htm#1727559 Filing: 000165495424001327
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
USD 0

Prior period

USD 0

2020-12-01 – 2021-11-30
Current period

USD 0

2021-12-01 – 2022-11-30

Exact inputs and evidence

0 − 0 = 0 USD

0 USD · 2020-12-01 – 2021-11-30
Inspect prior input Prior source
0 USD · 2021-12-01 – 2022-11-30
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Intellipharmaceutics International Inc. · 2022-11-30 Intellipharmaceutics International Inc. (edgar:1474835) Year-over-year change in Capital expenditure: 0 USD Concept: fundies:CapitalExpenditure Period: 2021-12-01 to 2022-11-30 Values: Latest reported Published: 2026-11-02T17:49:58Z Snapshot: 905284645addbe579a68ba4ce1d88a662b1b8ecbf27fcec4237c539a4d41962c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1474835?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 0 USD (2021-12-01 to 2022-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1474835/000165495424001327/ipii_20f.htm#1746636 Filing: 000165495424001327 Input fundies:CapitalExpenditure: 0 USD (2020-12-01 to 2021-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1474835/000165495424001327/ipii_20f.htm#1747348 Filing: 000165495424001327
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2022 2021-12-01 – 2022-11-30

Revenue USD 65,728 100% of revenue
Operating costs Derived USD 2.92 million 4,437% of revenue
Operating income −USD 2.85 million −4,337% of revenue
Tax, interest and other Derived USD 41,887 64% of revenue
Net income −USD 2.89 million −4,401% of revenue

Cash

Operating cash flow −USD 1.39 million −2,112% of revenue
Capital expenditure USD 0 0% of revenue
Free cash flow Derived −USD 1.39 million −2,112% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2012 Not shown: operating income or net income is not reported.
2013 Not shown: operating income or net income is not reported.
2014 Not shown: operating income or net income is not reported.
2015 Not shown: operating income or net income is not reported.
2017 Operating loss: operating costs were 250% of revenue.
2018 Operating loss: operating costs were 878% of revenue.
2019 Operating loss: operating costs were 325% of revenue.
2020 Operating loss: operating costs were 434% of revenue.
2021 Not shown: operating income or net income is not reported.
2022 Operating loss: operating costs were 4,437% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2012 2011-12-01 – 2012-11-30	107091	Unavailable	Unavailable	Unavailable	-6136865	-8690453 Derived	Source 2011-12-01 – 2012-11-30: 107091 USD Inspect Revenue Open source 2011-12-01 – 2012-11-30: -6136865 USD Inspect Net Income Open source 2011-12-01 – 2012-11-30: -7654361 USD Inspect Operating Cash Flow Open source 2011-12-01 – 2012-11-30: 1036092 USD Inspect Capital Expenditure Open source
2013 2012-12-01 – 2013-11-30	1527474	Unavailable	Unavailable	Unavailable	-11495017	-7048813 Derived	Source 2012-12-01 – 2013-11-30: 1527474 USD Inspect Revenue Open source 2012-12-01 – 2013-11-30: -11495017 USD Inspect Net Income Open source 2012-12-01 – 2013-11-30: -6926796 USD Inspect Operating Cash Flow Open source 2012-12-01 – 2013-11-30: 122017 USD Inspect Capital Expenditure Open source
2014 2013-12-01 – 2014-11-30	8769693	Unavailable	Unavailable	Unavailable	-3856353	-2483886 Derived	Source 2013-12-01 – 2014-11-30: 8769693 USD Inspect Revenue Open source 2013-12-01 – 2014-11-30: -3856353 USD Inspect Net Income Open source 2013-12-01 – 2014-11-30: -1714913 USD Inspect Operating Cash Flow Open source 2013-12-01 – 2014-11-30: 768973 USD Inspect Capital Expenditure Open source
2015 2014-12-01 – 2015-11-30	4093781	Unavailable	Unavailable	Unavailable	-7436388	-4212644 Derived	Source 2014-12-01 – 2015-11-30: 4093781 USD Inspect Revenue Open source 2014-12-01 – 2015-11-30: -7436388 USD Inspect Net Income Open source 2014-12-01 – 2015-11-30: -3782164 USD Inspect Operating Cash Flow Open source 2014-12-01 – 2015-11-30: 430480 USD Inspect Capital Expenditure Open source
2017 2016-12-01 – 2017-11-30	5504452	13770234 Derived	-8265782	591658 Derived	-8857440	-7929531 Derived	Source 2016-12-01 – 2017-11-30: 5504452 USD Inspect Revenue Open source 2016-12-01 – 2017-11-30: -8265782 USD Inspect Operating Income Open source 2016-12-01 – 2017-11-30: -8857440 USD Inspect Net Income Open source 2016-12-01 – 2017-11-30: -6105785 USD Inspect Operating Cash Flow Open source 2016-12-01 – 2017-11-30: 1823746 USD Inspect Capital Expenditure Open source
2018 2017-12-01 – 2018-11-30	1712731	15038997 Derived	-13326266	421214 Derived	-13747480	-12610138 Derived	Source 2017-12-01 – 2018-11-30: 1712731 USD Inspect Revenue Open source 2017-12-01 – 2018-11-30: -13326266 USD Inspect Operating Income Open source 2017-12-01 – 2018-11-30: -13747480 USD Inspect Net Income Open source 2017-12-01 – 2018-11-30: -12508960 USD Inspect Operating Cash Flow Open source 2017-12-01 – 2018-11-30: 101178 USD Inspect Capital Expenditure Open source
2019 2018-12-01 – 2019-11-30	3480516	11315466 Derived	-7834950	249696 Derived	-8084646	-6678151 Derived	Source 2018-12-01 – 2019-11-30: 3480516 USD Inspect Revenue Open source 2018-12-01 – 2019-11-30: -7834950 USD Inspect Operating Income Open source 2018-12-01 – 2019-11-30: -8084646 USD Inspect Net Income Open source 2018-12-01 – 2019-11-30: -6663677 USD Inspect Operating Cash Flow Open source 2018-12-01 – 2019-11-30: 14474 USD Inspect Capital Expenditure Open source
2020 2019-12-01 – 2020-11-30	1401517	6079825 Derived	-4678308	-1287343 Derived	-3390965	108233 Derived	Source 2019-12-01 – 2020-11-30: 1401517 USD Inspect Revenue Open source 2019-12-01 – 2020-11-30: -4678308 USD Inspect Operating Income Open source 2019-12-01 – 2020-11-30: -3390965 USD Inspect Net Income Open source 2019-12-01 – 2020-11-30: 112108 USD Inspect Operating Cash Flow Open source 2019-12-01 – 2020-11-30: 3875 USD Inspect Capital Expenditure Open source
2021 2020-12-01 – 2021-11-30	0	4173076 Derived	-4173076	972079 Derived	-5145155	-2461329 Derived	Source 2020-12-01 – 2021-11-30: 0 USD Inspect Revenue Open source 2020-12-01 – 2021-11-30: -4173076 USD Inspect Operating Income Open source 2020-12-01 – 2021-11-30: -5145155 USD Inspect Net Income Open source 2020-12-01 – 2021-11-30: -2461329 USD Inspect Operating Cash Flow Open source 2020-12-01 – 2021-11-30: 0 USD Inspect Capital Expenditure Open source
2022 2021-12-01 – 2022-11-30	65728	2916235 Derived	-2850507	41887 Derived	-2892394	-1388223 Derived	Source 2021-12-01 – 2022-11-30: 65728 USD Inspect Revenue Open source 2021-12-01 – 2022-11-30: -2850507 USD Inspect Operating Income Open source 2021-12-01 – 2022-11-30: -2892394 USD Inspect Net Income Open source 2021-12-01 – 2022-11-30: -1388223 USD Inspect Operating Cash Flow Open source 2021-12-01 – 2022-11-30: 0 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 65.7K 2022

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20122012-11-30	Revenue	107091	Revenue: 107091 Open source
20132013-11-30	Revenue	1527474	Revenue: 1527474 Open source
20142014-11-30	Revenue	8769693	Revenue: 8769693 Open source
20152015-11-30	Revenue	4093781	Revenue: 4093781 Open source
20172017-11-30	Revenue	5504452	Revenue: 5504452 Open source
20182018-11-30	Revenue	1712731	Revenue: 1712731 Open source
20192019-11-30	Revenue	3480516	Revenue: 3480516 Open source
20202020-11-30	Revenue	1401517	Revenue: 1401517 Open source
20212021-11-30	Revenue	0	Revenue: 0 Open source
20222022-11-30	Revenue	65728	Revenue: 65728 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-100% 2021

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20122012-11-30	Year over year	No prior comparable period	Revenue: 107091 Open source
20132013-11-30	Year over year	1,326.3%	Revenue: 1527474 Open source Revenue: 107091 Open source
20142014-11-30	Year over year	474.1%	Revenue: 8769693 Open source Revenue: 1527474 Open source
20152015-11-30	Year over year	-53.3%	Revenue: 4093781 Open source Revenue: 8769693 Open source
20172017-11-30	Year over year	No prior comparable period	Revenue: 5504452 Open source
20182018-11-30	Year over year	-68.9%	Revenue: 1712731 Open source Revenue: 5504452 Open source
20192019-11-30	Year over year	103.2%	Revenue: 3480516 Open source Revenue: 1712731 Open source
20202020-11-30	Year over year	-59.7%	Revenue: 1401517 Open source Revenue: 3480516 Open source
20212021-11-30	Year over year	-100%	Revenue: 0 Open source Revenue: 1401517 Open source
20222022-11-30	Year over year	No prior comparable period	Revenue: 65728 Open source Revenue: 0 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -4,336.8% 2022

Net margin -4,400.6% 2022

Free cash flow margin -2,112.1% 2022

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
2012-11-30	Operating margin	Not reported	Revenue: 107091 Open source
2013-11-30	Operating margin	Not reported	Revenue: 1527474 Open source
2014-11-30	Operating margin	Not reported	Revenue: 8769693 Open source
2015-11-30	Operating margin	Not reported	Revenue: 4093781 Open source
20172017-11-30	Operating margin	-150.2%	Operating Income: -8265782 Open source Revenue: 5504452 Open source
20182018-11-30	Operating margin	-778.1%	Operating Income: -13326266 Open source Revenue: 1712731 Open source
20192019-11-30	Operating margin	-225.1%	Operating Income: -7834950 Open source Revenue: 3480516 Open source
20202020-11-30	Operating margin	-333.8%	Operating Income: -4678308 Open source Revenue: 1401517 Open source
20212021-11-30	Operating margin	Not reported	Operating Income: -4173076 Open source Revenue: 0 Open source
20222022-11-30	Operating margin	-4,336.8%	Operating Income: -2850507 Open source Revenue: 65728 Open source
20122012-11-30	Net margin	-5,730.5%	Net Income: -6136865 Open source Revenue: 107091 Open source
20132013-11-30	Net margin	-752.6%	Net Income: -11495017 Open source Revenue: 1527474 Open source
20142014-11-30	Net margin	-44%	Net Income: -3856353 Open source Revenue: 8769693 Open source
20152015-11-30	Net margin	-181.7%	Net Income: -7436388 Open source Revenue: 4093781 Open source
20172017-11-30	Net margin	-160.9%	Net Income: -8857440 Open source Revenue: 5504452 Open source
20182018-11-30	Net margin	-802.7%	Net Income: -13747480 Open source Revenue: 1712731 Open source
20192019-11-30	Net margin	-232.3%	Net Income: -8084646 Open source Revenue: 3480516 Open source
20202020-11-30	Net margin	-241.9%	Net Income: -3390965 Open source Revenue: 1401517 Open source
20212021-11-30	Net margin	Not reported	Net Income: -5145155 Open source Revenue: 0 Open source
20222022-11-30	Net margin	-4,400.6%	Net Income: -2892394 Open source Revenue: 65728 Open source
20122012-11-30	Free cash flow margin	-8,115%	Revenue: 107091 Open source Operating Cash Flow: -7654361 Open source Capital Expenditure: 1036092 Open source
20132013-11-30	Free cash flow margin	-461.5%	Revenue: 1527474 Open source Operating Cash Flow: -6926796 Open source Capital Expenditure: 122017 Open source
20142014-11-30	Free cash flow margin	-28.3%	Revenue: 8769693 Open source Operating Cash Flow: -1714913 Open source Capital Expenditure: 768973 Open source
20152015-11-30	Free cash flow margin	-102.9%	Revenue: 4093781 Open source Operating Cash Flow: -3782164 Open source Capital Expenditure: 430480 Open source
20172017-11-30	Free cash flow margin	-144.1%	Revenue: 5504452 Open source Operating Cash Flow: -6105785 Open source Capital Expenditure: 1823746 Open source
20182018-11-30	Free cash flow margin	-736.3%	Revenue: 1712731 Open source Operating Cash Flow: -12508960 Open source Capital Expenditure: 101178 Open source
20192019-11-30	Free cash flow margin	-191.9%	Revenue: 3480516 Open source Operating Cash Flow: -6663677 Open source Capital Expenditure: 14474 Open source
20202020-11-30	Free cash flow margin	7.7%	Revenue: 1401517 Open source Operating Cash Flow: 112108 Open source Capital Expenditure: 3875 Open source
20212021-11-30	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -2461329 Open source Capital Expenditure: 0 Open source
20222022-11-30	Free cash flow margin	-2,112.1%	Revenue: 65728 Open source Operating Cash Flow: -1388223 Open source Capital Expenditure: 0 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -1.4M 2022

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20122012-11-30	Operating cash flow	-7654361	Operating Cash Flow: -7654361 Open source
20132013-11-30	Operating cash flow	-6926796	Operating Cash Flow: -6926796 Open source
20142014-11-30	Operating cash flow	-1714913	Operating Cash Flow: -1714913 Open source
20152015-11-30	Operating cash flow	-3782164	Operating Cash Flow: -3782164 Open source
20172017-11-30	Operating cash flow	-6105785	Operating Cash Flow: -6105785 Open source
20182018-11-30	Operating cash flow	-12508960	Operating Cash Flow: -12508960 Open source
20192019-11-30	Operating cash flow	-6663677	Operating Cash Flow: -6663677 Open source
20202020-11-30	Operating cash flow	112108	Operating Cash Flow: 112108 Open source
20212021-11-30	Operating cash flow	-2461329	Operating Cash Flow: -2461329 Open source
20222022-11-30	Operating cash flow	-1388223	Operating Cash Flow: -1388223 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -1.4M 2022

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20122012-11-30	Free cash flow	-8690453	Operating Cash Flow: -7654361 Open source Capital Expenditure: 1036092 Open source
20132013-11-30	Free cash flow	-7048813	Operating Cash Flow: -6926796 Open source Capital Expenditure: 122017 Open source
20142014-11-30	Free cash flow	-2483886	Operating Cash Flow: -1714913 Open source Capital Expenditure: 768973 Open source
20152015-11-30	Free cash flow	-4212644	Operating Cash Flow: -3782164 Open source Capital Expenditure: 430480 Open source
20172017-11-30	Free cash flow	-7929531	Operating Cash Flow: -6105785 Open source Capital Expenditure: 1823746 Open source
20182018-11-30	Free cash flow	-12610138	Operating Cash Flow: -12508960 Open source Capital Expenditure: 101178 Open source
20192019-11-30	Free cash flow	-6678151	Operating Cash Flow: -6663677 Open source Capital Expenditure: 14474 Open source
20202020-11-30	Free cash flow	108233	Operating Cash Flow: 112108 Open source Capital Expenditure: 3875 Open source
20212021-11-30	Free cash flow	-2461329	Operating Cash Flow: -2461329 Open source Capital Expenditure: 0 Open source
20222022-11-30	Free cash flow	-1388223	Operating Cash Flow: -1388223 Open source Capital Expenditure: 0 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

838.6% 2022

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20122012-11-30	Liabilities / assets	171.4%	Total Liabilities: 4242755 Open source Total Assets: 2474878 Open source
20132013-11-30	Liabilities / assets	236%	Total Liabilities: 10334574 Open source Total Assets: 4379501 Open source
20142014-11-30	Liabilities / assets	37.7%	Total Liabilities: 2965671 Open source Total Assets: 7875035 Open source
20152015-11-30	Liabilities / assets	102.6%	Total Liabilities: 5361985 Open source Total Assets: 5224299 Open source
20172017-11-30	Liabilities / assets	94.8%	Total Liabilities: 7010398 Open source Total Assets: 7396781 Open source
20182018-11-30	Liabilities / assets	64.2%	Total Liabilities: 7371920 Open source Total Assets: 11474227 Open source
20192019-11-30	Liabilities / assets	197.2%	Total Liabilities: 7488934 Open source Total Assets: 3796713 Open source
20202020-11-30	Liabilities / assets	286.4%	Total Liabilities: 9700644 Open source Total Assets: 3387055 Open source
20212021-11-30	Liabilities / assets	489%	Total Liabilities: 10251643 Open source Total Assets: 2096425 Open source
20222022-11-30	Liabilities / assets	838.6%	Total Liabilities: 12008767 Open source Total Assets: 1432032 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

0.04× 2022

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20122012-11-30	Current assets / current liabilities	0.42×	Current Assets: 939175 Open source Current Liabilities: 2235620 Open source
20132013-11-30	Current assets / current liabilities	0.56×	Current Assets: 2728415 Open source Current Liabilities: 4896552 Open source
20142014-11-30	Current assets / current liabilities	2.05×	Current Assets: 5984757 Open source Current Liabilities: 2923511 Open source
20152015-11-30	Current assets / current liabilities	0.56×	Current Assets: 2921116 Open source Current Liabilities: 5196325 Open source
20172017-11-30	Current assets / current liabilities	0.77×	Current Assets: 3563928 Open source Current Liabilities: 4647898 Open source
20182018-11-30	Current assets / current liabilities	1.64×	Current Assets: 8718234 Open source Current Liabilities: 5309420 Open source
20192019-11-30	Current assets / current liabilities	0.2×	Current Assets: 1523307 Open source Current Liabilities: 7488934 Open source
20202020-11-30	Current assets / current liabilities	0.15×	Current Assets: 1478987 Open source Current Liabilities: 9700644 Open source
20212021-11-30	Current assets / current liabilities	Not reported	Current Assets: 1102316 Open source
20222022-11-30	Current assets / current liabilities	0.04×	Current Assets: 492511 Open source Current Liabilities: 12008767 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2012 2011-12-01 – 2012-11-30	−USD 6.14 million Exact value Exact value: -6136865 USD 2011-12-01 – 2012-11-30: -6136865 USD Inspect Net Income Open source Share or cite Citation for Net Income · Intellipharmaceutics International Inc. · 2012-11-30 Intellipharmaceutics International Inc. (edgar:1474835) Net Income: -6136865 USD Concept: fundies:NetIncome Period: 2011-12-01 to 2012-11-30 Values: Latest reported Published: 2026-11-02T17:49:58Z Snapshot: 905284645addbe579a68ba4ce1d88a662b1b8ecbf27fcec4237c539a4d41962c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1474835/explain?concept=fundies%3ANetIncome&period=2012-11-30&surface=latest&period_type=duration&start=2011-12-01&unit=USD&dimensions= Input fundies:NetIncome: -6136865 USD (2011-12-01 to 2012-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1474835/000117184315001117/ipci-20141130.xml#146004 Filing: 000117184315001117 The citation records this snapshot. The page link may show a newer release later.	−USD 7.65 million Exact value Exact value: -7654361 USD 2011-12-01 – 2012-11-30: -7654361 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Intellipharmaceutics International Inc. · 2012-11-30 Intellipharmaceutics International Inc. (edgar:1474835) Operating Cash Flow: -7654361 USD Concept: fundies:OperatingCashFlow Period: 2011-12-01 to 2012-11-30 Values: Latest reported Published: 2026-11-02T17:49:58Z Snapshot: 905284645addbe579a68ba4ce1d88a662b1b8ecbf27fcec4237c539a4d41962c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1474835/explain?concept=fundies%3AOperatingCashFlow&period=2012-11-30&surface=latest&period_type=duration&start=2011-12-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -7654361 USD (2011-12-01 to 2012-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1474835/000117184315001117/ipci-20141130.xml#173624 Filing: 000117184315001117 The citation records this snapshot. The page link may show a newer release later.	USD 1.04 million Exact value Exact value: 1036092 USD 2011-12-01 – 2012-11-30: 1036092 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Intellipharmaceutics International Inc. · 2012-11-30 Intellipharmaceutics International Inc. (edgar:1474835) Capital Expenditure: 1036092 USD Concept: fundies:CapitalExpenditure Period: 2011-12-01 to 2012-11-30 Values: Latest reported Published: 2026-11-02T17:49:58Z Snapshot: 905284645addbe579a68ba4ce1d88a662b1b8ecbf27fcec4237c539a4d41962c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1474835/explain?concept=fundies%3ACapitalExpenditure&period=2012-11-30&surface=latest&period_type=duration&start=2011-12-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1036092 USD (2011-12-01 to 2012-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1474835/000117184315001117/ipci-20141130.xml#177435 Filing: 000117184315001117 The citation records this snapshot. The page link may show a newer release later.	−USD 8.69 million Calculation and evidence -7654361 − 1036092 USD Exact free cash flow: -8690453 USD 2011-12-01 – 2012-11-30: -7654361 USD · Inspect Operating Cash Flow · Source 2011-12-01 – 2012-11-30: 1036092 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Intellipharmaceutics International Inc. · 2012-11-30 Intellipharmaceutics International Inc. (edgar:1474835) Free cash flow: -8690453 USD Concept: free-cash-flow Period: 2011-12-01 to 2012-11-30 Values: Latest reported Published: 2026-11-02T17:49:58Z Snapshot: 905284645addbe579a68ba4ce1d88a662b1b8ecbf27fcec4237c539a4d41962c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1474835?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -7654361 USD (2011-12-01 to 2012-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1474835/000117184315001117/ipci-20141130.xml#173624 Filing: 000117184315001117 Input fundies:CapitalExpenditure: 1036092 USD (2011-12-01 to 2012-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1474835/000117184315001117/ipci-20141130.xml#177435 Filing: 000117184315001117 The citation records this snapshot. The page link may show a newer release later.
2013 2012-12-01 – 2013-11-30	−USD 11.5 million Exact value Exact value: -11495017 USD 2012-12-01 – 2013-11-30: -11495017 USD Inspect Net Income Open source Share or cite Citation for Net Income · Intellipharmaceutics International Inc. · 2013-11-30 Intellipharmaceutics International Inc. (edgar:1474835) Net Income: -11495017 USD Concept: fundies:NetIncome Period: 2012-12-01 to 2013-11-30 Values: Latest reported Published: 2026-11-02T17:49:58Z Snapshot: 905284645addbe579a68ba4ce1d88a662b1b8ecbf27fcec4237c539a4d41962c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1474835/explain?concept=fundies%3ANetIncome&period=2013-11-30&surface=latest&period_type=duration&start=2012-12-01&unit=USD&dimensions= Input fundies:NetIncome: -11495017 USD (2012-12-01 to 2013-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1474835/000117184316008685/ipci-20151130.xml#117983 Filing: 000117184316008685 The citation records this snapshot. The page link may show a newer release later.	−USD 6.93 million Exact value Exact value: -6926796 USD 2012-12-01 – 2013-11-30: -6926796 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Intellipharmaceutics International Inc. · 2013-11-30 Intellipharmaceutics International Inc. (edgar:1474835) Operating Cash Flow: -6926796 USD Concept: fundies:OperatingCashFlow Period: 2012-12-01 to 2013-11-30 Values: Latest reported Published: 2026-11-02T17:49:58Z Snapshot: 905284645addbe579a68ba4ce1d88a662b1b8ecbf27fcec4237c539a4d41962c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1474835/explain?concept=fundies%3AOperatingCashFlow&period=2013-11-30&surface=latest&period_type=duration&start=2012-12-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -6926796 USD (2012-12-01 to 2013-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1474835/000117184316008685/ipci-20151130.xml#144982 Filing: 000117184316008685 The citation records this snapshot. The page link may show a newer release later.	USD 122,017 Exact value Exact value: 122017 USD 2012-12-01 – 2013-11-30: 122017 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Intellipharmaceutics International Inc. · 2013-11-30 Intellipharmaceutics International Inc. (edgar:1474835) Capital Expenditure: 122017 USD Concept: fundies:CapitalExpenditure Period: 2012-12-01 to 2013-11-30 Values: Latest reported Published: 2026-11-02T17:49:58Z Snapshot: 905284645addbe579a68ba4ce1d88a662b1b8ecbf27fcec4237c539a4d41962c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1474835/explain?concept=fundies%3ACapitalExpenditure&period=2013-11-30&surface=latest&period_type=duration&start=2012-12-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 122017 USD (2012-12-01 to 2013-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1474835/000117184316008685/ipci-20151130.xml#148934 Filing: 000117184316008685 The citation records this snapshot. The page link may show a newer release later.	−USD 7.05 million Calculation and evidence -6926796 − 122017 USD Exact free cash flow: -7048813 USD 2012-12-01 – 2013-11-30: -6926796 USD · Inspect Operating Cash Flow · Source 2012-12-01 – 2013-11-30: 122017 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Intellipharmaceutics International Inc. · 2013-11-30 Intellipharmaceutics International Inc. (edgar:1474835) Free cash flow: -7048813 USD Concept: free-cash-flow Period: 2012-12-01 to 2013-11-30 Values: Latest reported Published: 2026-11-02T17:49:58Z Snapshot: 905284645addbe579a68ba4ce1d88a662b1b8ecbf27fcec4237c539a4d41962c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1474835?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -6926796 USD (2012-12-01 to 2013-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1474835/000117184316008685/ipci-20151130.xml#144982 Filing: 000117184316008685 Input fundies:CapitalExpenditure: 122017 USD (2012-12-01 to 2013-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1474835/000117184316008685/ipci-20151130.xml#148934 Filing: 000117184316008685 The citation records this snapshot. The page link may show a newer release later.
2014 2013-12-01 – 2014-11-30	−USD 3.86 million Exact value Exact value: -3856353 USD 2013-12-01 – 2014-11-30: -3856353 USD Inspect Net Income Open source Share or cite Citation for Net Income · Intellipharmaceutics International Inc. · 2014-11-30 Intellipharmaceutics International Inc. (edgar:1474835) Net Income: -3856353 USD Concept: fundies:NetIncome Period: 2013-12-01 to 2014-11-30 Values: Latest reported Published: 2026-11-02T17:49:58Z Snapshot: 905284645addbe579a68ba4ce1d88a662b1b8ecbf27fcec4237c539a4d41962c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1474835/explain?concept=fundies%3ANetIncome&period=2014-11-30&surface=latest&period_type=duration&start=2013-12-01&unit=USD&dimensions= Input fundies:NetIncome: -3856353 USD (2013-12-01 to 2014-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1474835/000117184316008685/ipci-20151130.xml#117858 Filing: 000117184316008685 The citation records this snapshot. The page link may show a newer release later.	−USD 1.71 million Exact value Exact value: -1714913 USD 2013-12-01 – 2014-11-30: -1714913 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Intellipharmaceutics International Inc. · 2014-11-30 Intellipharmaceutics International Inc. (edgar:1474835) Operating Cash Flow: -1714913 USD Concept: fundies:OperatingCashFlow Period: 2013-12-01 to 2014-11-30 Values: Latest reported Published: 2026-11-02T17:49:58Z Snapshot: 905284645addbe579a68ba4ce1d88a662b1b8ecbf27fcec4237c539a4d41962c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1474835/explain?concept=fundies%3AOperatingCashFlow&period=2014-11-30&surface=latest&period_type=duration&start=2013-12-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -1714913 USD (2013-12-01 to 2014-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1474835/000117184316008685/ipci-20151130.xml#144759 Filing: 000117184316008685 The citation records this snapshot. The page link may show a newer release later.	USD 768,973 Exact value Exact value: 768973 USD 2013-12-01 – 2014-11-30: 768973 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Intellipharmaceutics International Inc. · 2014-11-30 Intellipharmaceutics International Inc. (edgar:1474835) Capital Expenditure: 768973 USD Concept: fundies:CapitalExpenditure Period: 2013-12-01 to 2014-11-30 Values: Latest reported Published: 2026-11-02T17:49:58Z Snapshot: 905284645addbe579a68ba4ce1d88a662b1b8ecbf27fcec4237c539a4d41962c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1474835/explain?concept=fundies%3ACapitalExpenditure&period=2014-11-30&surface=latest&period_type=duration&start=2013-12-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 768973 USD (2013-12-01 to 2014-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1474835/000117184316008685/ipci-20151130.xml#148753 Filing: 000117184316008685 The citation records this snapshot. The page link may show a newer release later.	−USD 2.48 million Calculation and evidence -1714913 − 768973 USD Exact free cash flow: -2483886 USD 2013-12-01 – 2014-11-30: -1714913 USD · Inspect Operating Cash Flow · Source 2013-12-01 – 2014-11-30: 768973 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Intellipharmaceutics International Inc. · 2014-11-30 Intellipharmaceutics International Inc. (edgar:1474835) Free cash flow: -2483886 USD Concept: free-cash-flow Period: 2013-12-01 to 2014-11-30 Values: Latest reported Published: 2026-11-02T17:49:58Z Snapshot: 905284645addbe579a68ba4ce1d88a662b1b8ecbf27fcec4237c539a4d41962c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1474835?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -1714913 USD (2013-12-01 to 2014-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1474835/000117184316008685/ipci-20151130.xml#144759 Filing: 000117184316008685 Input fundies:CapitalExpenditure: 768973 USD (2013-12-01 to 2014-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1474835/000117184316008685/ipci-20151130.xml#148753 Filing: 000117184316008685 The citation records this snapshot. The page link may show a newer release later.
2015 2014-12-01 – 2015-11-30	−USD 7.44 million Exact value Exact value: -7436388 USD 2014-12-01 – 2015-11-30: -7436388 USD Inspect Net Income Open source Share or cite Citation for Net Income · Intellipharmaceutics International Inc. · 2015-11-30 Intellipharmaceutics International Inc. (edgar:1474835) Net Income: -7436388 USD Concept: fundies:NetIncome Period: 2014-12-01 to 2015-11-30 Values: Latest reported Published: 2026-11-02T17:49:58Z Snapshot: 905284645addbe579a68ba4ce1d88a662b1b8ecbf27fcec4237c539a4d41962c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1474835/explain?concept=fundies%3ANetIncome&period=2015-11-30&surface=latest&period_type=duration&start=2014-12-01&unit=USD&dimensions= Input fundies:NetIncome: -7436388 USD (2014-12-01 to 2015-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1474835/000117184316008685/ipci-20151130.xml#117733 Filing: 000117184316008685 The citation records this snapshot. The page link may show a newer release later.	−USD 3.78 million Exact value Exact value: -3782164 USD 2014-12-01 – 2015-11-30: -3782164 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Intellipharmaceutics International Inc. · 2015-11-30 Intellipharmaceutics International Inc. (edgar:1474835) Operating Cash Flow: -3782164 USD Concept: fundies:OperatingCashFlow Period: 2014-12-01 to 2015-11-30 Values: Latest reported Published: 2026-11-02T17:49:58Z Snapshot: 905284645addbe579a68ba4ce1d88a662b1b8ecbf27fcec4237c539a4d41962c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1474835/explain?concept=fundies%3AOperatingCashFlow&period=2015-11-30&surface=latest&period_type=duration&start=2014-12-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -3782164 USD (2014-12-01 to 2015-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1474835/000117184316008685/ipci-20151130.xml#144536 Filing: 000117184316008685 The citation records this snapshot. The page link may show a newer release later.	USD 430,480 Exact value Exact value: 430480 USD 2014-12-01 – 2015-11-30: 430480 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Intellipharmaceutics International Inc. · 2015-11-30 Intellipharmaceutics International Inc. (edgar:1474835) Capital Expenditure: 430480 USD Concept: fundies:CapitalExpenditure Period: 2014-12-01 to 2015-11-30 Values: Latest reported Published: 2026-11-02T17:49:58Z Snapshot: 905284645addbe579a68ba4ce1d88a662b1b8ecbf27fcec4237c539a4d41962c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1474835/explain?concept=fundies%3ACapitalExpenditure&period=2015-11-30&surface=latest&period_type=duration&start=2014-12-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 430480 USD (2014-12-01 to 2015-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1474835/000117184316008685/ipci-20151130.xml#148572 Filing: 000117184316008685 The citation records this snapshot. The page link may show a newer release later.	−USD 4.21 million Calculation and evidence -3782164 − 430480 USD Exact free cash flow: -4212644 USD 2014-12-01 – 2015-11-30: -3782164 USD · Inspect Operating Cash Flow · Source 2014-12-01 – 2015-11-30: 430480 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Intellipharmaceutics International Inc. · 2015-11-30 Intellipharmaceutics International Inc. (edgar:1474835) Free cash flow: -4212644 USD Concept: free-cash-flow Period: 2014-12-01 to 2015-11-30 Values: Latest reported Published: 2026-11-02T17:49:58Z Snapshot: 905284645addbe579a68ba4ce1d88a662b1b8ecbf27fcec4237c539a4d41962c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1474835?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -3782164 USD (2014-12-01 to 2015-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1474835/000117184316008685/ipci-20151130.xml#144536 Filing: 000117184316008685 Input fundies:CapitalExpenditure: 430480 USD (2014-12-01 to 2015-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1474835/000117184316008685/ipci-20151130.xml#148572 Filing: 000117184316008685 The citation records this snapshot. The page link may show a newer release later.
2017 2016-12-01 – 2017-11-30	−USD 8.86 million Exact value Exact value: -8857440 USD 2016-12-01 – 2017-11-30: -8857440 USD Inspect Net Income Open source Share or cite Citation for Net Income · Intellipharmaceutics International Inc. · 2017-11-30 Intellipharmaceutics International Inc. (edgar:1474835) Net Income: -8857440 USD Concept: fundies:NetIncome Period: 2016-12-01 to 2017-11-30 Values: Latest reported Published: 2026-11-02T17:49:58Z Snapshot: 905284645addbe579a68ba4ce1d88a662b1b8ecbf27fcec4237c539a4d41962c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1474835/explain?concept=fundies%3ANetIncome&period=2017-11-30&surface=latest&period_type=duration&start=2016-12-01&unit=USD&dimensions= Input fundies:NetIncome: -8857440 USD (2016-12-01 to 2017-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1474835/000165495420003539/ipci-20191130.xml#146909 Filing: 000165495420003539 The citation records this snapshot. The page link may show a newer release later.	−USD 6.11 million Exact value Exact value: -6105785 USD 2016-12-01 – 2017-11-30: -6105785 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Intellipharmaceutics International Inc. · 2017-11-30 Intellipharmaceutics International Inc. (edgar:1474835) Operating Cash Flow: -6105785 USD Concept: fundies:OperatingCashFlow Period: 2016-12-01 to 2017-11-30 Values: Latest reported Published: 2026-11-02T17:49:58Z Snapshot: 905284645addbe579a68ba4ce1d88a662b1b8ecbf27fcec4237c539a4d41962c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1474835/explain?concept=fundies%3AOperatingCashFlow&period=2017-11-30&surface=latest&period_type=duration&start=2016-12-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -6105785 USD (2016-12-01 to 2017-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1474835/000165495420003539/ipci-20191130.xml#169355 Filing: 000165495420003539 The citation records this snapshot. The page link may show a newer release later.	USD 1.82 million Exact value Exact value: 1823746 USD 2016-12-01 – 2017-11-30: 1823746 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Intellipharmaceutics International Inc. · 2017-11-30 Intellipharmaceutics International Inc. (edgar:1474835) Capital Expenditure: 1823746 USD Concept: fundies:CapitalExpenditure Period: 2016-12-01 to 2017-11-30 Values: Latest reported Published: 2026-11-02T17:49:58Z Snapshot: 905284645addbe579a68ba4ce1d88a662b1b8ecbf27fcec4237c539a4d41962c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1474835/explain?concept=fundies%3ACapitalExpenditure&period=2017-11-30&surface=latest&period_type=duration&start=2016-12-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1823746 USD (2016-12-01 to 2017-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1474835/000165495420003539/ipci-20191130.xml#172986 Filing: 000165495420003539 The citation records this snapshot. The page link may show a newer release later.	−USD 7.93 million Calculation and evidence -6105785 − 1823746 USD Exact free cash flow: -7929531 USD 2016-12-01 – 2017-11-30: -6105785 USD · Inspect Operating Cash Flow · Source 2016-12-01 – 2017-11-30: 1823746 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Intellipharmaceutics International Inc. · 2017-11-30 Intellipharmaceutics International Inc. (edgar:1474835) Free cash flow: -7929531 USD Concept: free-cash-flow Period: 2016-12-01 to 2017-11-30 Values: Latest reported Published: 2026-11-02T17:49:58Z Snapshot: 905284645addbe579a68ba4ce1d88a662b1b8ecbf27fcec4237c539a4d41962c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1474835?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -6105785 USD (2016-12-01 to 2017-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1474835/000165495420003539/ipci-20191130.xml#169355 Filing: 000165495420003539 Input fundies:CapitalExpenditure: 1823746 USD (2016-12-01 to 2017-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1474835/000165495420003539/ipci-20191130.xml#172986 Filing: 000165495420003539 The citation records this snapshot. The page link may show a newer release later.
2018 2017-12-01 – 2018-11-30	−USD 13.75 million Exact value Exact value: -13747480 USD 2017-12-01 – 2018-11-30: -13747480 USD Inspect Net Income Open source Share or cite Citation for Net Income · Intellipharmaceutics International Inc. · 2018-11-30 Intellipharmaceutics International Inc. (edgar:1474835) Net Income: -13747480 USD Concept: fundies:NetIncome Period: 2017-12-01 to 2018-11-30 Values: Latest reported Published: 2026-11-02T17:49:58Z Snapshot: 905284645addbe579a68ba4ce1d88a662b1b8ecbf27fcec4237c539a4d41962c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1474835/explain?concept=fundies%3ANetIncome&period=2018-11-30&surface=latest&period_type=duration&start=2017-12-01&unit=USD&dimensions= Input fundies:NetIncome: -13747480 USD (2017-12-01 to 2018-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1474835/000165495421003662/ipci-20201130.xml#135134 Filing: 000165495421003662 The citation records this snapshot. The page link may show a newer release later.	−USD 12.51 million Exact value Exact value: -12508960 USD 2017-12-01 – 2018-11-30: -12508960 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Intellipharmaceutics International Inc. · 2018-11-30 Intellipharmaceutics International Inc. (edgar:1474835) Operating Cash Flow: -12508960 USD Concept: fundies:OperatingCashFlow Period: 2017-12-01 to 2018-11-30 Values: Latest reported Published: 2026-11-02T17:49:58Z Snapshot: 905284645addbe579a68ba4ce1d88a662b1b8ecbf27fcec4237c539a4d41962c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1474835/explain?concept=fundies%3AOperatingCashFlow&period=2018-11-30&surface=latest&period_type=duration&start=2017-12-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -12508960 USD (2017-12-01 to 2018-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1474835/000165495421003662/ipci-20201130.xml#156384 Filing: 000165495421003662 The citation records this snapshot. The page link may show a newer release later.	USD 101,178 Exact value Exact value: 101178 USD 2017-12-01 – 2018-11-30: 101178 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Intellipharmaceutics International Inc. · 2018-11-30 Intellipharmaceutics International Inc. (edgar:1474835) Capital Expenditure: 101178 USD Concept: fundies:CapitalExpenditure Period: 2017-12-01 to 2018-11-30 Values: Latest reported Published: 2026-11-02T17:49:58Z Snapshot: 905284645addbe579a68ba4ce1d88a662b1b8ecbf27fcec4237c539a4d41962c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1474835/explain?concept=fundies%3ACapitalExpenditure&period=2018-11-30&surface=latest&period_type=duration&start=2017-12-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 101178 USD (2017-12-01 to 2018-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1474835/000165495421003662/ipci-20201130.xml#160449 Filing: 000165495421003662 The citation records this snapshot. The page link may show a newer release later.	−USD 12.61 million Calculation and evidence -12508960 − 101178 USD Exact free cash flow: -12610138 USD 2017-12-01 – 2018-11-30: -12508960 USD · Inspect Operating Cash Flow · Source 2017-12-01 – 2018-11-30: 101178 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Intellipharmaceutics International Inc. · 2018-11-30 Intellipharmaceutics International Inc. (edgar:1474835) Free cash flow: -12610138 USD Concept: free-cash-flow Period: 2017-12-01 to 2018-11-30 Values: Latest reported Published: 2026-11-02T17:49:58Z Snapshot: 905284645addbe579a68ba4ce1d88a662b1b8ecbf27fcec4237c539a4d41962c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1474835?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -12508960 USD (2017-12-01 to 2018-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1474835/000165495421003662/ipci-20201130.xml#156384 Filing: 000165495421003662 Input fundies:CapitalExpenditure: 101178 USD (2017-12-01 to 2018-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1474835/000165495421003662/ipci-20201130.xml#160449 Filing: 000165495421003662 The citation records this snapshot. The page link may show a newer release later.
2019 2018-12-01 – 2019-11-30	−USD 8.08 million Exact value Exact value: -8084646 USD 2018-12-01 – 2019-11-30: -8084646 USD Inspect Net Income Open source Share or cite Citation for Net Income · Intellipharmaceutics International Inc. · 2019-11-30 Intellipharmaceutics International Inc. (edgar:1474835) Net Income: -8084646 USD Concept: fundies:NetIncome Period: 2018-12-01 to 2019-11-30 Values: Latest reported Published: 2026-11-02T17:49:58Z Snapshot: 905284645addbe579a68ba4ce1d88a662b1b8ecbf27fcec4237c539a4d41962c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1474835/explain?concept=fundies%3ANetIncome&period=2019-11-30&surface=latest&period_type=duration&start=2018-12-01&unit=USD&dimensions= Input fundies:NetIncome: -8084646 USD (2018-12-01 to 2019-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1474835/000165495422006198/ipii_20fa.htm#1967548 Filing: 000165495422006198 The citation records this snapshot. The page link may show a newer release later.	−USD 6.66 million Exact value Exact value: -6663677 USD 2018-12-01 – 2019-11-30: -6663677 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Intellipharmaceutics International Inc. · 2019-11-30 Intellipharmaceutics International Inc. (edgar:1474835) Operating Cash Flow: -6663677 USD Concept: fundies:OperatingCashFlow Period: 2018-12-01 to 2019-11-30 Values: Latest reported Published: 2026-11-02T17:49:58Z Snapshot: 905284645addbe579a68ba4ce1d88a662b1b8ecbf27fcec4237c539a4d41962c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1474835/explain?concept=fundies%3AOperatingCashFlow&period=2019-11-30&surface=latest&period_type=duration&start=2018-12-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -6663677 USD (2018-12-01 to 2019-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1474835/000165495422006198/ipii_20fa.htm#1919766 Filing: 000165495422006198 The citation records this snapshot. The page link may show a newer release later.	USD 14,474 Exact value Exact value: 14474 USD 2018-12-01 – 2019-11-30: 14474 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Intellipharmaceutics International Inc. · 2019-11-30 Intellipharmaceutics International Inc. (edgar:1474835) Capital Expenditure: 14474 USD Concept: fundies:CapitalExpenditure Period: 2018-12-01 to 2019-11-30 Values: Latest reported Published: 2026-11-02T17:49:58Z Snapshot: 905284645addbe579a68ba4ce1d88a662b1b8ecbf27fcec4237c539a4d41962c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1474835/explain?concept=fundies%3ACapitalExpenditure&period=2019-11-30&surface=latest&period_type=duration&start=2018-12-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 14474 USD (2018-12-01 to 2019-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1474835/000165495422006198/ipii_20fa.htm#1944586 Filing: 000165495422006198 The citation records this snapshot. The page link may show a newer release later.	−USD 6.68 million Calculation and evidence -6663677 − 14474 USD Exact free cash flow: -6678151 USD 2018-12-01 – 2019-11-30: -6663677 USD · Inspect Operating Cash Flow · Source 2018-12-01 – 2019-11-30: 14474 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Intellipharmaceutics International Inc. · 2019-11-30 Intellipharmaceutics International Inc. (edgar:1474835) Free cash flow: -6678151 USD Concept: free-cash-flow Period: 2018-12-01 to 2019-11-30 Values: Latest reported Published: 2026-11-02T17:49:58Z Snapshot: 905284645addbe579a68ba4ce1d88a662b1b8ecbf27fcec4237c539a4d41962c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1474835?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -6663677 USD (2018-12-01 to 2019-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1474835/000165495422006198/ipii_20fa.htm#1919766 Filing: 000165495422006198 Input fundies:CapitalExpenditure: 14474 USD (2018-12-01 to 2019-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1474835/000165495422006198/ipii_20fa.htm#1944586 Filing: 000165495422006198 The citation records this snapshot. The page link may show a newer release later.
2020 2019-12-01 – 2020-11-30	−USD 3.39 million Exact value Exact value: -3390965 USD 2019-12-01 – 2020-11-30: -3390965 USD Inspect Net Income Open source Share or cite Citation for Net Income · Intellipharmaceutics International Inc. · 2020-11-30 Intellipharmaceutics International Inc. (edgar:1474835) Net Income: -3390965 USD Concept: fundies:NetIncome Period: 2019-12-01 to 2020-11-30 Values: Latest reported Published: 2026-11-02T17:49:58Z Snapshot: 905284645addbe579a68ba4ce1d88a662b1b8ecbf27fcec4237c539a4d41962c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1474835/explain?concept=fundies%3ANetIncome&period=2020-11-30&surface=latest&period_type=duration&start=2019-12-01&unit=USD&dimensions= Input fundies:NetIncome: -3390965 USD (2019-12-01 to 2020-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1474835/000165495424001327/ipii_20f.htm#1775684 Filing: 000165495424001327 The citation records this snapshot. The page link may show a newer release later.	USD 112,108 Exact value Exact value: 112108 USD 2019-12-01 – 2020-11-30: 112108 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Intellipharmaceutics International Inc. · 2020-11-30 Intellipharmaceutics International Inc. (edgar:1474835) Operating Cash Flow: 112108 USD Concept: fundies:OperatingCashFlow Period: 2019-12-01 to 2020-11-30 Values: Latest reported Published: 2026-11-02T17:49:58Z Snapshot: 905284645addbe579a68ba4ce1d88a662b1b8ecbf27fcec4237c539a4d41962c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1474835/explain?concept=fundies%3AOperatingCashFlow&period=2020-11-30&surface=latest&period_type=duration&start=2019-12-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 112108 USD (2019-12-01 to 2020-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1474835/000165495424001327/ipii_20f.htm#1728241 Filing: 000165495424001327 The citation records this snapshot. The page link may show a newer release later.	USD 3,875 Exact value Exact value: 3875 USD 2019-12-01 – 2020-11-30: 3875 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Intellipharmaceutics International Inc. · 2020-11-30 Intellipharmaceutics International Inc. (edgar:1474835) Capital Expenditure: 3875 USD Concept: fundies:CapitalExpenditure Period: 2019-12-01 to 2020-11-30 Values: Latest reported Published: 2026-11-02T17:49:58Z Snapshot: 905284645addbe579a68ba4ce1d88a662b1b8ecbf27fcec4237c539a4d41962c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1474835/explain?concept=fundies%3ACapitalExpenditure&period=2020-11-30&surface=latest&period_type=duration&start=2019-12-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3875 USD (2019-12-01 to 2020-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1474835/000165495424001327/ipii_20f.htm#1748011 Filing: 000165495424001327 The citation records this snapshot. The page link may show a newer release later.	USD 108,233 Calculation and evidence 112108 − 3875 USD Exact free cash flow: 108233 USD 2019-12-01 – 2020-11-30: 112108 USD · Inspect Operating Cash Flow · Source 2019-12-01 – 2020-11-30: 3875 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Intellipharmaceutics International Inc. · 2020-11-30 Intellipharmaceutics International Inc. (edgar:1474835) Free cash flow: 108233 USD Concept: free-cash-flow Period: 2019-12-01 to 2020-11-30 Values: Latest reported Published: 2026-11-02T17:49:58Z Snapshot: 905284645addbe579a68ba4ce1d88a662b1b8ecbf27fcec4237c539a4d41962c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1474835?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 112108 USD (2019-12-01 to 2020-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1474835/000165495424001327/ipii_20f.htm#1728241 Filing: 000165495424001327 Input fundies:CapitalExpenditure: 3875 USD (2019-12-01 to 2020-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1474835/000165495424001327/ipii_20f.htm#1748011 Filing: 000165495424001327 The citation records this snapshot. The page link may show a newer release later.
2021 2020-12-01 – 2021-11-30	−USD 5.15 million Exact value Exact value: -5145155 USD 2020-12-01 – 2021-11-30: -5145155 USD Inspect Net Income Open source Share or cite Citation for Net Income · Intellipharmaceutics International Inc. · 2021-11-30 Intellipharmaceutics International Inc. (edgar:1474835) Net Income: -5145155 USD Concept: fundies:NetIncome Period: 2020-12-01 to 2021-11-30 Values: Latest reported Published: 2026-11-02T17:49:58Z Snapshot: 905284645addbe579a68ba4ce1d88a662b1b8ecbf27fcec4237c539a4d41962c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1474835/explain?concept=fundies%3ANetIncome&period=2021-11-30&surface=latest&period_type=duration&start=2020-12-01&unit=USD&dimensions= Input fundies:NetIncome: -5145155 USD (2020-12-01 to 2021-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1474835/000165495424001327/ipii_20f.htm#1775481 Filing: 000165495424001327 The citation records this snapshot. The page link may show a newer release later.	−USD 2.46 million Exact value Exact value: -2461329 USD 2020-12-01 – 2021-11-30: -2461329 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Intellipharmaceutics International Inc. · 2021-11-30 Intellipharmaceutics International Inc. (edgar:1474835) Operating Cash Flow: -2461329 USD Concept: fundies:OperatingCashFlow Period: 2020-12-01 to 2021-11-30 Values: Latest reported Published: 2026-11-02T17:49:58Z Snapshot: 905284645addbe579a68ba4ce1d88a662b1b8ecbf27fcec4237c539a4d41962c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1474835/explain?concept=fundies%3AOperatingCashFlow&period=2021-11-30&surface=latest&period_type=duration&start=2020-12-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -2461329 USD (2020-12-01 to 2021-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1474835/000165495424001327/ipii_20f.htm#1727559 Filing: 000165495424001327 The citation records this snapshot. The page link may show a newer release later.	USD 0 Exact value Exact value: 0 USD 2020-12-01 – 2021-11-30: 0 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Intellipharmaceutics International Inc. · 2021-11-30 Intellipharmaceutics International Inc. (edgar:1474835) Capital Expenditure: 0 USD Concept: fundies:CapitalExpenditure Period: 2020-12-01 to 2021-11-30 Values: Latest reported Published: 2026-11-02T17:49:58Z Snapshot: 905284645addbe579a68ba4ce1d88a662b1b8ecbf27fcec4237c539a4d41962c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1474835/explain?concept=fundies%3ACapitalExpenditure&period=2021-11-30&surface=latest&period_type=duration&start=2020-12-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 0 USD (2020-12-01 to 2021-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1474835/000165495424001327/ipii_20f.htm#1747348 Filing: 000165495424001327 The citation records this snapshot. The page link may show a newer release later.	−USD 2.46 million Calculation and evidence -2461329 − 0 USD Exact free cash flow: -2461329 USD 2020-12-01 – 2021-11-30: -2461329 USD · Inspect Operating Cash Flow · Source 2020-12-01 – 2021-11-30: 0 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Intellipharmaceutics International Inc. · 2021-11-30 Intellipharmaceutics International Inc. (edgar:1474835) Free cash flow: -2461329 USD Concept: free-cash-flow Period: 2020-12-01 to 2021-11-30 Values: Latest reported Published: 2026-11-02T17:49:58Z Snapshot: 905284645addbe579a68ba4ce1d88a662b1b8ecbf27fcec4237c539a4d41962c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1474835?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -2461329 USD (2020-12-01 to 2021-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1474835/000165495424001327/ipii_20f.htm#1727559 Filing: 000165495424001327 Input fundies:CapitalExpenditure: 0 USD (2020-12-01 to 2021-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1474835/000165495424001327/ipii_20f.htm#1747348 Filing: 000165495424001327 The citation records this snapshot. The page link may show a newer release later.
2022 2021-12-01 – 2022-11-30	−USD 2.89 million Exact value Exact value: -2892394 USD 2021-12-01 – 2022-11-30: -2892394 USD Inspect Net Income Open source Share or cite Citation for Net Income · Intellipharmaceutics International Inc. · 2022-11-30 Intellipharmaceutics International Inc. (edgar:1474835) Net Income: -2892394 USD Concept: fundies:NetIncome Period: 2021-12-01 to 2022-11-30 Values: Latest reported Published: 2026-11-02T17:49:58Z Snapshot: 905284645addbe579a68ba4ce1d88a662b1b8ecbf27fcec4237c539a4d41962c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1474835/explain?concept=fundies%3ANetIncome&period=2022-11-30&surface=latest&period_type=duration&start=2021-12-01&unit=USD&dimensions= Input fundies:NetIncome: -2892394 USD (2021-12-01 to 2022-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1474835/000165495424001327/ipii_20f.htm#1775241 Filing: 000165495424001327 The citation records this snapshot. The page link may show a newer release later.	−USD 1.39 million Exact value Exact value: -1388223 USD 2021-12-01 – 2022-11-30: -1388223 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Intellipharmaceutics International Inc. · 2022-11-30 Intellipharmaceutics International Inc. (edgar:1474835) Operating Cash Flow: -1388223 USD Concept: fundies:OperatingCashFlow Period: 2021-12-01 to 2022-11-30 Values: Latest reported Published: 2026-11-02T17:49:58Z Snapshot: 905284645addbe579a68ba4ce1d88a662b1b8ecbf27fcec4237c539a4d41962c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1474835/explain?concept=fundies%3AOperatingCashFlow&period=2022-11-30&surface=latest&period_type=duration&start=2021-12-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -1388223 USD (2021-12-01 to 2022-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1474835/000165495424001327/ipii_20f.htm#1726876 Filing: 000165495424001327 The citation records this snapshot. The page link may show a newer release later.	USD 0 Exact value Exact value: 0 USD 2021-12-01 – 2022-11-30: 0 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Intellipharmaceutics International Inc. · 2022-11-30 Intellipharmaceutics International Inc. (edgar:1474835) Capital Expenditure: 0 USD Concept: fundies:CapitalExpenditure Period: 2021-12-01 to 2022-11-30 Values: Latest reported Published: 2026-11-02T17:49:58Z Snapshot: 905284645addbe579a68ba4ce1d88a662b1b8ecbf27fcec4237c539a4d41962c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1474835/explain?concept=fundies%3ACapitalExpenditure&period=2022-11-30&surface=latest&period_type=duration&start=2021-12-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 0 USD (2021-12-01 to 2022-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1474835/000165495424001327/ipii_20f.htm#1746636 Filing: 000165495424001327 The citation records this snapshot. The page link may show a newer release later.	−USD 1.39 million Calculation and evidence -1388223 − 0 USD Exact free cash flow: -1388223 USD 2021-12-01 – 2022-11-30: -1388223 USD · Inspect Operating Cash Flow · Source 2021-12-01 – 2022-11-30: 0 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Intellipharmaceutics International Inc. · 2022-11-30 Intellipharmaceutics International Inc. (edgar:1474835) Free cash flow: -1388223 USD Concept: free-cash-flow Period: 2021-12-01 to 2022-11-30 Values: Latest reported Published: 2026-11-02T17:49:58Z Snapshot: 905284645addbe579a68ba4ce1d88a662b1b8ecbf27fcec4237c539a4d41962c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1474835?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -1388223 USD (2021-12-01 to 2022-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1474835/000165495424001327/ipii_20f.htm#1726876 Filing: 000165495424001327 Input fundies:CapitalExpenditure: 0 USD (2021-12-01 to 2022-11-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1474835/000165495424001327/ipii_20f.htm#1746636 Filing: 000165495424001327 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

319 filings · 2,439 latest values · 2,439 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001474835, 1474835, IPCIF, edgar:1474835, ipci

Also known as INTELLIPHARMACEUTICS INTERNATIONAL INC., IntelliPharmaCeutics International Inc., Intellipharmaceutics International Inc.

Intellipharmaceutics International Inc.

Latest quarter

Revenue

Operating margin

Operating cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2022 2021-12-01 – 2022-11-30

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation